137 related articles for article (PubMed ID: 2153453)
1. Contribution of elevated protein turnover and anorexia to cachexia in patients with hepatocellular carcinoma.
O'Keefe SJ; Ogden J; Ramjee G; Rund J
Cancer Res; 1990 Feb; 50(4):1226-30. PubMed ID: 2153453
[TBL] [Abstract][Full Text] [Related]
2. Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover.
Dworzak F; Ferrari P; Gavazzi C; Maiorana C; Bozzetti F
Cancer; 1998 Jan; 82(1):42-8. PubMed ID: 9428478
[TBL] [Abstract][Full Text] [Related]
3. Defective nonoxidative leucine degradation and endogenous leucine flux in cirrhosis during an amino acid infusion.
McCullough AJ; Mullen KD; Kalhan SC
Hepatology; 1998 Nov; 28(5):1357-64. PubMed ID: 9794922
[TBL] [Abstract][Full Text] [Related]
4. Leucine kinetics in patients with benign disease, non-weight-losing cancer, and cancer cachexia: studies at the whole-body and tissue level and the response to nutritional support.
Shaw JH; Humberstone DA; Douglas RG; Koea J
Surgery; 1991 Jan; 109(1):37-50. PubMed ID: 1984636
[TBL] [Abstract][Full Text] [Related]
5. In vivo measurement of leucine metabolism with stable isotopes in normal subjects and in those with cirrhosis fed conventional and branched-chain amino acid-enriched diets.
Millikan WJ; Henderson JM; Galloway JR; Warren WD; Matthews DE; McGhee A; Kutner MH
Surgery; 1985 Sep; 98(3):405-13. PubMed ID: 4035563
[TBL] [Abstract][Full Text] [Related]
6. Altered leucine metabolism in noncachectic sarcoma patients.
Inculet RI; Stein TP; Peacock JL; Leskiw M; Maher M; Gorschboth CM; Norton JA
Cancer Res; 1987 Sep; 47(17):4746-9. PubMed ID: 3621173
[TBL] [Abstract][Full Text] [Related]
7. Altered amino acid kinetics in rats with progressive tumor growth.
Kawamura I; Moldawer LL; Keenan RA; Batist G; Bothe A; Bistrian BR; Blackburn GL
Cancer Res; 1982 Mar; 42(3):824-9. PubMed ID: 7059980
[TBL] [Abstract][Full Text] [Related]
8. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
10. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
11. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.
Paradis V; Degos F; Dargère D; Pham N; Belghiti J; Degott C; Janeau JL; Bezeaud A; Delforge D; Cubizolles M; Laurendeau I; Bedossa P
Hepatology; 2005 Jan; 41(1):40-7. PubMed ID: 15690480
[TBL] [Abstract][Full Text] [Related]
12. Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Nov; 404():1-303. PubMed ID: 12621514
[TBL] [Abstract][Full Text] [Related]
13. Dietary control of protein turnover.
Arnal M; Obled C; Attaix D; Patureau-Mirand P; Bonin D
Diabete Metab; 1987; 13(6):630-42. PubMed ID: 3329127
[TBL] [Abstract][Full Text] [Related]
14. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
15. Protein turnover in acute and chronic liver disease.
O'Keefe SJ; Abraham RR; Davis M; Williams R
Acta Chir Scand Suppl; 1981; 507():91-101. PubMed ID: 6797209
[TBL] [Abstract][Full Text] [Related]
16. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
Wu W; Yao DF; Yuan YM; Fan JW; Lu XF; Li XH; Qiu LW; Zong L; Wu XH
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):538-44. PubMed ID: 17085339
[TBL] [Abstract][Full Text] [Related]
17. Plasma amino acid levels in patients with colorectal cancers and liver cirrhosis with hepatocellular carcinoma.
Lee JC; Chen MJ; Chang CH; Tiai YF; Lin PW; Lai HS; Wang ST
Hepatogastroenterology; 2003; 50(53):1269-73. PubMed ID: 14571716
[TBL] [Abstract][Full Text] [Related]
18. Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma.
Hsu PI; Chow NH; Lai KH; Yang HB; Chan SH; Lin XZ; Cheng JS; Huang JS; Ger LP; Huang SM; Yen MY; Yang YF
Anticancer Res; 1997; 17(4A):2803-9. PubMed ID: 9252719
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against ox-LDL serum levels in patients with hepatocellular carcinoma.
Motta M; Pistone G; Franzone AM; Romeo MA; Di Mauro S; Giugno I; Ruello P; Malaguarnera M
Panminerva Med; 2003 Mar; 45(1):69-73. PubMed ID: 12682623
[TBL] [Abstract][Full Text] [Related]
20. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma.
Scholz A; Rehm VA; Rieke S; Derkow K; Schulz P; Neumann K; Koch I; Pascu M; Wiedenmann B; Berg T; Schott E
Am J Gastroenterol; 2007 Nov; 102(11):2471-81. PubMed ID: 17581268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
